Participants:0–17 years · 18–64 years · 65+ years
Substances:Autologous T-Cells Ex Vivo Modified With A Lentiviral Vector Encoding A Chimeric Antigen Receptor Specific For Cd1A
Sponsor:Onechain Immunotherapeutics S.L.

Contact Research Centre

T-cell type acute leukaemia+1

Recruiting

InvestigationalNo placebo

Study on the Safety and Effectiveness of OC-1 Therapy for Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or Lymphoma

InvestigationalNo placebo

Spain

Participants:0–17 years · 18–64 years · 65+ years
Substances:Autologous T-Cells Ex Vivo Modified With A Lentiviral Vector Encoding A Chimeric Antigen Receptor Specific For Cd1A
Sponsor:Onechain Immunotherapeutics S.L.

Contact Research Centre

T-cell type acute leukaemia

Recruiting

Registered drugNo placebo

Study on the Safety and Effectiveness of Isatuximab and Drug Combination for Adults with Relapsed or Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Bortezomib
Sponsor:Goethe University Frankfurt

Contact Research Centre

T-cell type acute leukaemia+1

Recruiting

Registered drugNo placebo

Study of CD7-CART01, Cyclophosphamide, and Fludarabine Phosphate for Children and Young Adults with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma

Registered drugNo placebo

Italy

Participants:0–17 years · 18–64 years
Substances:Cd7-Cart01
Sponsor:Ospedale Pediatrico Bambino Gesu'

Contact Research Centre

T-cell type acute leukaemia

Not yet recruiting

Registered drugNo placebo

Evaluating venetoclax with drug combination in relapsed/refractory T‑cell acute lymphoblastic leukemia patients

Registered drugNo placebo

Czechia

Participants:0–17 years · 18–64 years · 65+ years
Substances:Azacitidine
Sponsor:Centre Hospitalier De Versailles

Contact Research Centre

See all trials →

T-cell type acute leukaemia

Clinical trials for T-cell type acute leukaemia

T-cell type acute leukaemia+2

Study of CART84 Treatment for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia

T-cell type acute leukaemia+1

Long-term Follow-up Study for Patients with Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma Treated with OC-1 Cells

T-cell type acute leukaemia+1

Study on the Safety and Effectiveness of OC-1 Therapy for Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or Lymphoma

T-cell type acute leukaemia

Study on the Safety and Effectiveness of Isatuximab and Drug Combination for Adults with Relapsed or Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia

T-cell type acute leukaemia+1

Study of CD7-CART01, Cyclophosphamide, and Fludarabine Phosphate for Children and Young Adults with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma

T-cell type acute leukaemia

Evaluating venetoclax with drug combination in relapsed/refractory T‑cell acute lymphoblastic leukemia patients

Filter the trials

Prefer not to search? Our Concierge searches the trials for you.